Grove Biopharma, Inc. | $30,000,000 | (Apr 25, 2025)
Northwood | $30,000,000 | (Apr 25, 2025)
Steadily Insurance Company | $30,000,000 | (Apr 25, 2025)
Predicta Biosciences
United States
- Cambridge, Massachusetts
- 17/07/2024
- Seed
- $5,200,000
Predicta Biosciences is a precision oncology company integrating cutting edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Predicta's diagnostic product portfolio removes the burden of bone-marrow biopsies, through small blood-based samples, and enables best-in-class treatment decision-making for immunotherapies. Utilizing the data from the diagnostic platform, Predicta has an in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development.
- Industry Biotechnology Research
- Website https://www.predictabiosciences.com/
- LinkedIn https://www.linkedin.com/company/predicta-biosciences/
Related People
Kate (Gallagher) CavesFounder
United States -
Greater Boston
Executive Leader with Business Development, Corporate Development, Marketing and deep technical background in Therapeutic Development and Diagnostic tools. Passionate about the intersection of Biology, Healthcare, and AI.
Alternative Payments | $22,000,000 | (Apr 25, 2025)
Listen Labs | $27,000,000 | (Apr 25, 2025)
Lace | $14,000,000 | (Apr 25, 2025)
RISE® Robotics | $1,500,000 | (Apr 25, 2025)
Ravenna | $15,000,000 | (Apr 25, 2025)
ChEmpower Corporation | $18,700,000 | (Apr 25, 2025)
Theo | $20,000,000 | (Apr 25, 2025)
Isembard | $9,000,000 | (Apr 25, 2025)
Electra(US) | $186,000,000 | (Apr 25, 2025)